Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog
Xuanyan Xu

Xuanyan Xu

Sr. Marketing Manager, Life Sciences Audience at Elsevier

Connect with Xuanyan Xu on LinkedIn
Follow Xuanyan Xu on Twitter
Website:

About the author: Seeing academic discoveries translated into life-changing applications is exciting--and, even more so, being a part of it. As a senior marketing manager for Life Sciences Audience, I bring a strong understanding of pharmaceutical industry needs, advancing technologies and customer insights to drive the product go-to-market strategy, planning and execution. Everything I write about here is geared towards issues that I deeply care about: open innovation, emerging approaches in data science and the evolving regulatory framework. Feel free to reach out to me about these topics. It is my desire to deliver my understanding and knowledge back to our communities.

Posts by Xuanyan Xu

‘Tis the season to have your own pharma-themed film festival

Posted on December 23rd, 2019 in Pharma R&D

The warmest family celebration of the year is almost here! All my friends and colleagues around me have started thinking about the best ways to spend this year’s family gathering. Well, if you are like me—a geeky introvert who enjoys time alone—nothing goes better with family parties and eating huge amounts of food than relaxing on the couch and binge-watching movies and TV shows.

(more…)

Healthy China initiative emphasizes prevention

Posted on December 12th, 2019 in Pharma R&D

China has made huge strides in its national health since the 1950s when life expectancy was less than 45 years (today, it’s 76-79 years). I was born there in the 1980s and grew up through the beginning phase of economic reform and opening up to the world. The hospital infrastructure and quality of services has gotten much better, and there has been a growth in community healthcare providers and pharmacies. My parents and their generation say the entire healthcare system has improved tremendously. Government, universities and corporations have also been giving a great deal of attention to this area, especially with big data and AI trending.

(more…)

Elsevier uses machine learning to benefit pharmacovigilance

Posted on November 7th, 2019 in Pharmacovigilance

Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.

(more…)

Elsevier research will be featured at upcoming Safety Pharmacology Society meeting

Posted on September 4th, 2019 in Pharma R&D

Network showing human adverse events that are concordant in one or more species (Source: Matthew Clark & Thomas Steiger-Hartmann, Regulatory Toxicology and Pharmacology, July 2018)

The 2019 Safety Pharmacology Society meeting will be in Barcelona from September 23-26, and the event is bringing together industry professionals to share best practices, enjoy networking opportunities, hear keynote speeches from thought leaders, and learn about hot research topics from experts in the field.

(more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6